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Abstract 
Virological failure in management of HIV-1 infection has been reported to be between 11 to 24% after 12 months 
of treatment. Out of these, acquired or transmitted drug resistance mutations have been reported at 71% to 90% 
in Sub-Sahara Africa. In this cross-sectional study we aimed to determine virological failure and drug resistance 
mutations in HIV-1 infected patients on ART attending Kayanza district hospital, Burundi. Patients were 
recruited using a purposive sampling technique. After informed consent, 4mL of venous blood was collected 
from each patient. The blood was separated into plasma and cells for various laboratory assays. Plasma viral 
loads were quantified using the Abbott m2000rt system. Polymerase chain reaction using gene specific primers 
was done after extraction of nucleic acids from plasma with >1000 copies/ mL, followed by sequencing of all 
amplified samples. Drug resistance was determined using the IAS and Stanford University database, with 
phylogenetic analyses done using the neighbor joining method.Two hundred patients were recruited; 13% of the 
respondents had virological failure associated with multiple sex partners (adjusted odds ratio (aOR, 0.154 , p 
=0.016) and irregularity in taking medications (aOR: 0.4 , p=0.014). Fifteen samples were successfully 
sequenced; 80% (12/15) were HIV-1 subtype C, 7% (1/15) subtype A, and 13% (2/15) were HIV-1 subtype A1. 
Of these, 87.5% had at least one mutation (NRTI or NNRTI), while 12.5 % did not carry any Drug Resistance 
Mutations. The most common drug resistance mutations were M183V, T215V M41L, E44D, L74I, L210W and 
K65R, K103N, Y188H. The prevalence of virological failure was established at 13%.Our findings showed 
possible gaps in the last 90% of the 90-90-90 WHO target by 2020. The results highlight the need for intense 
viral load and resistance testing for patients to improve overall treatment outcome. Some strategies are needed to 
improve adherence counselling and drug resistance mutation testing should be implemented to monitor HIV-1 
patients on ART in Burundi.  
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1. Introduction 
The increasing use of ART has increased the lifespan of HIV infected persons and thus the lifespan of such a 
population has now moved closer to HIV non infected populations (Nsanzimana et al., 2015). Despite of these 
successes, Virological failure have been reported in many studies one year after initiation of HAART in the 
patients on ART despite effective combination therapy. This will inevitably be accompanied by the emergence 
and transmission of drug resistance viruses (Hamers et al, 2013) . Also, even when optimal adherence to therapy 
is supported ,Virological failure at some point during the ART have been reported in 10% to 30% of individuals 
receiving a first-line NRTI/NNRTI-containing treatment regimen and the majority of these individuals are 
expected to acquire NRTI- and/or NNRTI-resistant viruses in sub-Sahara Africa (Barth et al., 2010). Drug 
resistance viruses is a major factor contributing to treatment failure and develops when viral replication 
continues in the presence of selective drug pressure and the cause should be the impotent regimens, ineffectively 
treated compartments, suboptimal adherence and pharmacological hurdles(Bulage et al., 2017).In Burundi, many 
interventions for control and prevention, such as PMTCT, care services for treatment with ARV drugs have been 
implemented. As of 2014, the most recent year for which an estimate is available, 1.3% of the population in 
Burundi was living with HIV with approximately 4,700 annual deaths attributed to AIDS. According to the 
Spectrum estimates (Version 2015), the number of people living with HIV (PLHIV) in Burundi was 
81,965(adults and children), amounting to an estimated ART coverage of 51% (56% among adult, and 17% 
among children) (Summary, 2016).To date, the use of CD4 count and Viral load testing in Burundi have been 
implemented as monitoring of treatment failure but little is known about the prevalence of virological failure and 
patterns of drug resistance in HIV-infected patients in Burundi. Our study was aimed at determining the 
prevalence of virological failure and describing drug resistance mutations in HIV-1 infected patients on ART 
over 12 months of first line therapy, attending Kayanza district hospital, Burundi.  
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2. Material and Methods 
2.1. Study design 
This was a descriptive cross sectional study. 
 
2.2. Study site 
This study was carried out at Kayanza District Hospital; located at Kayanza Centre, in Kayanza Province, 
Burundi. It is the capital city of Kayanza Province.  
 
2.3 Study population 
These were HIV-1 infected patients on ART over 12 months attending Kayanza district hospital. The study 
population included patients living with HIV and AIDS, males and females, from 2 year old and over, who were 
on first line ART for more than 12 Months. 
 
2.4 Epidemiological data collection 
A questionnaire was used to collect demographic data, clinical, drugs experienced and any other characteristics. 
More patients’ information’s were also obtained through desk review of the clinical and laboratory records from 
the patient’s files. 
 
2.5 Sample collection and handling 
This was a purposive sampling method where all patients who met the inclusion criteria were recruited into the 
study. They were requested to voluntary sign the informed consent before enrolled in the study. Up to 4 mL of 
venous blood was collected from each patient in Ethylene diamine tetra acetic Acid (EDTA) tubes and shipped 
to Ngonzi regional hospital and Burundi National Reference Laboratory (NRL) for further processing. Plasma 
with suspected virological failure (Viral load > 1000 copies/mL) were stored at -80oC  and later shipped to the 
Kenya Medical Research Institute (KEMRI), in Nairobi – Kenya, where further testing and analysis were 
performed. 
 
2.6 Statistical analysis 
Analysis were done using SPSS version 21. We used descriptive statistics to analyse socio-demographic data, 
clinical and immunological outcomes and virological outcomes. The data was reported as percentages. 
Multinomial logistic regression was used to adjust for odds of viral outcomes associated with various 
demographic factors (like gender, age, religion, education status, marital status, income source, presence of other 
partners and reminders to take ARVs) as well as other medical factors (like taking alcohol, irregularity in taking 
drugs, taking TB drugs, line of ARV medication, date of staring treatment, CD4 initial count and CD4 count at 
study time). The results were expressed as odds ratios. (OR) with 95% confidence intervals (CIs). 
 
2.7 Ethical clearance 
The study was approved by the Burundi National Ethical Committee (BERC: 25/03/2018). To maintain the 
confidentiality, a unique ID number was given to each specimen, and written consent or assent from each patient 
was obtained. No names or direct identifiers of the participants were published anywhere. 
 
2.8 Viral load testing 
Viral load assay for plasma samples was done using Real Time HIV-1 assay Kit Abbott molecular Inc.; Des 
Plaines, IL 60018, USA), which has an internal Quality Control system, with automated Abbott m2000rt™ 
System and was perfomed according to the manufacturer’s instruction. Lower limit of detection was 40 copies of 
HIV RNA / mL.Samples with viral load > 1000 copies/ml were considered for Sequencing and Genotyping. 
 
2.9 Extraction of RNA and Reverse Transcription 
The RNA was extracted from plasma samples using the Qiagen RNA extraction Kit (QIAamp® Viral RNA mini 
kit Qiagen RNA extraction protocol) according to the manufacturers’ instructions (Luvai et al., 2015).The 
template (10 µl of extracted RNA) was reverse transcribed in a total volume of 20 µl with 1 µl dNTP, 2 µl 
primer, 4µl 5× RT buffer, 2 µl DTT, 0.25 µl Ranse OUT and 1.0 µl SuperScriptTM III RNase H− RT 
(Invitrogen, Carlsbad, CA2).The RNA, primer and dNTPs were first incubated at 65°C for 5 minutes, then 4° for 
5 minutes, and the remaining reagents were added for cDNA synthesis at 25°C for 5 minutes, 50°C for 40 
minutes, followed by 70°C 15 minutes (Khamadi et al., 2005). 
 
2.10 Polymerase Chain Reaction (PCR) 
The cDNA was used as template to amplify the region of interest for HIV-1 drug resistance. The reagents were 
thawed on ice to preserve their integrity. The total volume of outer PCR was 25μL reaction volume with a 
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mixture containing 3 μL of the DNA template to be amplified, 2.5 μL of 10X buffer (without magnesium 
chloride) ,0.3 μL of each RT18 (RT 18(5’-GGAAACCAAAAATGATAGGGGGAATTGGAGG-3’) ) and 
KS104 primers (KS 104(5’-TGATTGCCCAATTTAGTTTTCCCACTAA-3’), 0.5μL dNTP, 2.0 μL Mgcl2, 0.2 
μL of Taq polymerase and 16.2 μL of distilled water(Nyamache et al., 2011). The cycling conditions were 1 
cycle of 95˚C for 10 min and 35 cycles of 95˚C for 30 s, annealing at 55˚C for 30 s, and 72˚C for 1 min, and final 
extension of 72˚C for 10 min. From the first-round PCR products, 3 μL was used as a template to  make  25μL 
for the second reaction volume with the second set of primers ;KS101(KS101(5’-
GTAGGACCTACACCTGTTCAACATAATTGGAAG-3’) and KS102 KS102(5’ 
CCCATCCAAAGAAATGGAGGAGGTTCTTTCTGATC-3’) using the same cycling conditions(Nyamache et 
al., 2011). The nested PCR product were run on a 2% agarose gel and electrophoresed at a voltage of 100 for 20 
minutes(Kiptoo et al., 2013). 
 
2.11 Sequencing 
The amplicons from the nested PCR were sequenced. Using the ABI 3730xl DNA Analyzer (96 capillary type), 
Sequencing reactions were performed in the DNA Master cycler pro 384(Eppendorf) using the ABI BigDye® 
Terminator v3ext Cycle Sequencing Kit (Applied Biosystems). Single-pass sequencing was performed on each 
template using selected primers. The fluorescent-labeled fragments were purified from the unincorporated 
terminators with the BigDye XTerminator® Purification Kit (Applied Biosystems). The samples were injected to 
electrophoresis in an ABI 3730xl DNA Analyzer (Applied Biosystems).A reaction mixture containing the 
following reagents was used for sequencing PCR: Thirteen (13) µl RNase free double distilled H2O,5x 
sequencing buffer,1.5 µl primers of 1 µM sense and antisense primer,1.0 µl big dye terminator and 1.0 µl PCR 
product making up a total reaction volume of 20 µl  (Songok et al., 2004). The PCR tubes containing the 
samples were placed into the thermocycler under the following programmed conditions; Initial PCR activation 
step 96°C for 2 minutes; 30 cycles of: denaturation for 10 seconds at 96°C, annealing for 10 seconds at 50°C; 
extension for 4 minute at 60°C and thereafter the samples were held at 4°C (Kiptoo et al ., 2013;Lihana et al., 
2009) .  
 
2.12 HIV-1 Subtyping 
The Sequences derived in this study were subjected to BLAST and REGA search tools to determine subtype 
diversity. Reference sequences were selected from Los Alamos HIV database. The sequences were aligned and 
gaps removed using BioEdit. The tree topology was obtained using the neighbour-joining method .A 
phylogenetic tree was constructed using neighbour joining method in MEGA 6 software (Tamura et al., 2013). 
Alignment of DNA sequences was performed using the CLUSTALW program (http://www.clustal.org).  The 
pairwise distance matrix was estimated using the Kimura two parameter model with the MEGAv6 software 
package (http://www.megasoftware.net). Bootstrap re-sampling (1000 data sets) of the multiple alignments was 
performed to set the statistical robustness of the tree. The tree profile was visualized with tree view PPC version 
1.65 (Foley et al., 2015.) 
 
2.14 Genotypic drug resistance mutations identification 
Drug Resistance mutations, defined using the 2018 update of the International AIDS Society (IAS) USA, and 
were manually located in each RT sequence following the IAS-USA nomenclature. Genotypic interpretation of 
the resistance mutations was carried out using the Stanford HIVdb Algorithm ,version 6.0.11 (Stanford 
University, Palo Alto, CA).Drug resistance was categorized in the tree levels: Susceptible(S),Intermediate(I) and 
Resistant (R).All sequences associated with high level resistance according to Stanford IAS Algorithms were 
considered to be resistance. 
 
3. Results 
3.1. Baseline characteristics of the study participants 
A total of 200 patients who met the inclusion criteria were included in the study. All patients were ARV 
experienced based on 2008 Burundi National guidelines, which proposed combination of Zidovudine (AZT), 
lamivudine (3TC) and Nevirapine or Efavirenz are the most commonly prescribed first-line. The age distribution 
was unimodal and it peaked at 45 years (range 3 to 67 years). More than half of the respondents (n=172) were 
above 18years and female accounted for 55% (n=110). Stratification by religion, 73.5% (n=147) were christian - 
catholics while 52% (n=104) were married On the level of education, 82.5% (n=165) reported completing 
primary school while farming as occupation was reported by 65% (n=131) with 94% (n=188) reporting to earn 
below BIF 200.The study realized that 12.5% (25) of the patients were on tuberculosis (TB) medications while 
57% (114)   had been on antiretroviral (ARV) therapy for between six to ten years.  In total 51%, (102) did not 
have detectable viral loads while (39%, (78) had a CD4 count of >350 cells/mm3.While at the time of starting the 
ARV medications 68% (137) of the respondents had a CD4 count of >350 cells/mm3.  text On ARV medication, 
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56.5% (113) of the respondents reported using tenofovir (TDF), lamividune (3TC) and Efavirenz (EFV) drug 
regimen, but TDF,tenofovor-3TC,lamividune-NVP,nevirapine;zidovudine AZT+lamividune, 
3TC+NVP,nevirapine; Duovir; Duovir+ EFV, efavirenz were also used . 
 
3.2. Virological outcomes 
At the time of the study, 51% (102/200) of the respondents did not have detectable viral load (VL < 40 
copies/ml), 34%, n=72/200 were between 400 and 999 copies/ml while 13%, (26/200) had virological failure 
(VL ≥1000 copies/ml). Virological failure was strongly with the presence of other partners; p =0.016 (Table 1).  
Table 1. Relationship between virological failure and demographic characteristics among HIV positive 
patients attending Kayanza district Hospital (n= 26). 
Variable Viral Failure aOR  P Value 
Gender 
Male 14 
1.2 0.337 
Female 12 
    25     
Age 
12-Feb 4 0.8 0.915 
13-17 3 0.994 0.997 
>18 years 19 1   
Religion 
Catholic 18 0.7 0.566 
Protestant 1 0.3 0.182 
Muslim 7 1   
Educational status 
primary 22 0.62 0.256 
secondary 3 0.87 0.732 
university 1 1   
Marital Status 
Single 9 3 0.504 
Married 7 0.13 0.667 
Divorced 2 0.2 0.142 
Widowed 8 1   
Income source 
Farmer 15 1.1 0.943 
Formal employment 1 1.7 0.673 
Informal employment 10 1   
Missing dose 
Yes 3 0.154 0.016 
No 23 1   
Reminded to take ARVs 
Yes 22 4.3 0.072 
No 4 1   
Viral failure was significantly correlated with irregularity in taking medications (adjusted odds ratio (aOR):0.4, 
p=0.014) (Table 2). 
 
Table 2.Relationship between viral failure and other medical and social factors among HIV positive 
patients attending Kayanza district Hospital (n= 26). 
Variable Viral Failure aOR  P Value 
Taking alcohol 
Yes 6 0.8 
0.711 
No 20 1 
Missing Dose 
Yes 5 0.4 
0.014 
No 21 1 
Taking TB Drugs 
Yes 4 0.3 
0.251 
No 23 1 
Line of ARV Medication 
First line*** 17 5.2 
0.075 
Second line** 9 1 
Time on ART 
1 10 0.7 0.81 
2 15 1.1 0.994 
3 1 1   
CD4 initial count 
<200 cells/mm3 9 1.8 0.412 
200-350 cells/mm3 7 0.881 0.833 
>350 cells/mm3 10 1   
CD4 Count at study time 
<200 cells/mm3 4 1.7 0.598 
200-350 cells/mm3 6 0.6 0.409 
>350 cells/mm3 17 0 1 
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***First line drug regimen                         ** Second line drug regimen 
Adolescent and adults 
2NRTI+NNRTI                                            2NRTI+PI/r 
TDF/3TC/EFV (first choice) t                     ABC/3TC + ATV/r (first choice)  
TDF/3TC+ NVP (alternative)                      ABC/3TC + ATZ/r (alternative) 
AZT/3TC/NVP (alternative)                       ABC/3TC + ATZ/r (alternative) 
Under 3 years: 
NRTI                                                               NNRTI 
ABC+3TC+LPV/r (first choice)                    AZT+3TC+RAL (first choice) 
ABC+3TC+LPV/r over 3 (second line)               ABC+3TC+RAL (alternative) 
3-10 years: 
NRTI                                                                NNRTI 
ABC+3TC+EFV (first choice)                      AZT+3TC+ATV/r (first choice) 
ABC+3TC+NVP (alternative)              AZT+3TC+ATV/r (alternative) AZT+3TC+NVP (alternative                       
ABC+3TC+ATV/r (alternative) 
 
3.2. Phylogenetic characterization of HIV-1 variants 
Genotype sequencing was performed on 26 samples with virological failure (HIV-1 RNA ≥1,000 cop/mL). 
Fifteen (15) samples were successfully sequenced. From these, 80% (12/15) were HIV-1 subtype C, 7% (1/15) 
were subtype A, and 13% (2/15) were HIV-1 subtype A1 (Table 2). The Phylogenetic tree , illustrated  with 
reference sequences   labelled using their gene bank accession numbers and country of origin show that HIV-1 
subtype C clustered with those of Burundi, Rwanda, and Tanzania. The samples with subtype A clustered with 
those from Burundi and DRC (Figure.1). 
 AM260246 BU C
 EU251735 TA C
 PA9_BUR
 AM260238 BU C
 KF544221 KE
 BU02_BUR
 AM260321 BU C
 BU01_BUR
 PA13_BUR
 PA12_BUR
 PA15_BUR
 BU03_BUR
 PA6_BUR
 AB285761 ETH C
 AY102486 SS
 AF009410  RW A1C
 PA4_BUR
 PA10_BUR
 PA3_BUR
 PA11_BUR
 AY829288 BSW C
 MH709846 SA C
 AY829269 BSW
 KX540737 SA C
 AY158533 SA C
 AY713413 MAL C
 AY772535 CAM G
 AY253311 TA
 AF033819 HIVGen
 PA7_BUR
 AF286240 RDC A2
 KC018813 RWA
 AM260255 BU C
 AF330783 FRA A
 M62320 UG
 PA8_BUR
 EU110095 KE A1
 JX236669 UG A
 AF410218 UG A1D
 PA2_BUR
 AF407150 KE A1D
 AF361879 TA A1C
 AF077336 DRC F
 AY887255 TA  
Figure1. Phylogenetic tree illustrated using the samples with reference sequences from Los Alamos data 
base. 
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The above phylogenetic tree illustrating the evolutionary relationships of HIV-1 subtypes found from the 
samples in relation to reference sequence from Los Alamos database. The samples are labeled with PA_BUR 
and PA_BUR with blue triangle followed by the number and subtype and the references are labeled by their 
accessory number, the subtypes and the country of origin. 
 
3.3. Drug resistance mutations analysis 
Our study showed that 80% (12/15) had at least one mutation (NRTI or NNRTI), while 20 % (3/15) did not carry 
any drug resistance mutations. Based on drug class, the most common drug resistance mutations were against 
NNRTI 80% (12/15) while DRM against NRTI were 47 % 7/15. The most common drug resistance mutations 
were M183V, M41L, E44D, L74I, L210W, K65R, K103N, E188A and Y188H (Table 3). Finally, minor 
mutations were found like V179I in two patients, K101Q in 5 patients and S68G in one patient. For NRTIs, the 
HIV drug resistance mutations found were against FTC, 3TC, D4T and TDF while for the NNRTI the mutations 
found were against EFV and NVP (Table 3). 
Table 3. Resistance mutations by drug class and subtypes in HIV patients attending Kayanza district 
hospital. 
ID 
Sequences 
Subtype
s DRMs 
NRTIs NNRTIs 
  HDRMs DRUGS HDRMs DRUGS 
BU01_BUR C M184V FTC,3TC K103N NVP,EFV 
BU02_BUR C None - K103N NVP,EFV 
BU03_BUR C M184V FTC,3TC K103N, Y188H EFV,NVP 
PA2_BUR A K65R,M184V 
FTC,ABC,DD
I K103N, EFV,NVP 
PA3_BUR C None - K103N EFV,NVP 
PA4_BUR C None - K103N EFV,NVP 
PA6_BUR C M184V 3TC,FTC K103N EFV,NVP 
PA7_BUR A1 None - None None 
PA8_BUR A1 None - None - 
PA9_BUR C None - None - 
PA10_BUR C None - K103N EFV,NVP 
PA11_BUR C None - K103N EFV,NVP 
PA12_BUR C M184V FTC,3TC K103N EFV,NVP 
PA13_BUR C 
M41L,E44D,L74I,
M184V,L210W 
ABC,FTC,DD
,3TC K103N,E138A EFV,NVP 
PA15_BUR C M184V FTC,3TC K103N EFV,NVP 
 
4. Discussion  
To our knowledge this was the first descriptive study on virological and HIV drug resistance mutations outcomes 
conducted in HIV patients after 12 months of treatment in Burundi. All patients were ARV experienced based on 
2008 Burundi National guidelines, which proposed combination of Zidovudine (AZT), lamivudine (3TC) and 
Nevirapine or Efavirenz as the commonly prescribed first-line treatment combinations. In this unimodal 
population with 86% above 18 years with 55% mainly females, the treatment failure of 13% raises a concern to 
the public health system, as low level transmitted resistance could already be taking place in the general 
population. This success of HIV drug treatment a met the WHO recommendation of >85% of patients on ART 
suppressing HIV-1 VL after 12 months of treatment. At 87 % viral suppression after 12 months on treatment, 
Burundi exhibits a potential to reach the third 90% of the 90-90-90 target recently set by UNAIDS Likewise, 
studies conducted in other countries in Resources Limited Settings such as Rwanda, Tanzania show virological 
suppressed of 88.1% and 86% respectively (Ndahimana et al., 2016; Rusine et al., 2013;Hawkins et al., 2016) 
but  are high contrary  to those found in Latine America and in Ethiopia. (Cesar et al., 2015; Endalamaw et al., 
2018). The reason for geographic area where carried the study should not be excluded in this discordant 
findings .In our study, Viral failure was significantly correlated with irregularity in taking medications missing 
dose. As Kayanza Hospital is a rural health facility, poor adherence to distance-related antiretroviral therapy may 
be observed and could certainly lead to virological failure. The findings highlight why adherence is good, not 
only for the prevention of morbidity, mortality and transmission, but also for the prevention of HIV drug 
resistance. Our results are not surprising because it has long been known that low adhesion leads to virological 
failure and resistance to anti-HIV drugs. (Luvai et al. ,2015; Etta et al., 2017, Endalamaw et al., 2018).Although, 
even the national HIV program in Burundi provides basic membership counseling, outreach activities should be 
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planned to improve adherence interventions for ARV patients and minimize follow-up losses. Our finding show 
also association between virological failures with the presence of other partners .This should be the evidence 
from HIV patients on ARV who have sex with those who have already the acquired or transmitted drug 
resistance. Also, multiple infections with different strains of the virus and other sexually transmitted infections 
can lead to ART drug resistance hence virological failure (Dessie.,2011) .This could potentially be due to 
transmission of resistance virus from other partners ,an assertion that calls for further investigation of the rate of 
transmitted resistance. In our study, fifteen samples were successfully sequenced; 80% (12/15) were HIV-1 
subtype C, 7% (1/15) were subtype A, and 13% (2/15) were HIV-1 subtype A1. HIV-1 subtype C is the most 
prevalent worldwide and is the major HIV-1 subtype non subtype B in some countries of southern and eastern 
Africa, Asia and the Middle East, where most infections occur ( Luvai et al.,2015).  Our findings concurred with 
previous studies conducted in Burundi (Vidal et al., 2007;) and  have been reported with an important fraction of 
HIV infection in east Africa(Delatorre & Bello., 2012; Lihana et al.,2012).Also sexual transmission of this 
subtype is also suggested to be more than that of subtype A (Abecasis et al., 2013). Althoug, our finding is 
particularly not similar to those found in Rwanda , one of borders country (Rusine et al., 2013). This should 
mention the absence of a cross transmission from these two countries. We suggest that a study should be done to 
reveal the origin of that predominant of subtype C in Burundi, wich is not predominant in borders countries. 
(Rusine et al., 2013; Luvai et al., 2015)From this study, subtype C was observed to have a high number of drug 
associated mutations. The M184V was the highest mutation (33%) in NRTI and is known to confer very high 
resistance against NRTI. For NRTI, Subtype C viruses develop resistance against non-nucleoside reverse-
transcriptase inhibitors of K103N at 77% and this are known to be common in cases of treatment failure ( Rusine 
et al., 2013) . Also, Grossman et al., 2004 in their study showed that Subtype C viruses develop resistance 
against nonnucleoside reverse-transcriptase inhibitors through the K103N mutations. Due to the small number of 
sample size, it is difficult to determine effective treatment of the different subtypes. Our finding showed that 
80% (12/15) had at least one NRTI or NNRTI. One reason might have been the low sub-optimal adherence. Our 
results indicate that reliable measurements of drug adherence are needed. This results should not be unexpected 
as the drug resistance mutations was done from patients with virological failure .Also, the drug resistance 
mutation between 79 % to 85 % have been reported from many authors in sub-Saharan Africa like in Rwanda, 
Kenya and Tanzania ( Rusine et al., 2013., Luvai.,2016.; Hawkins et al., 2016) . Althoug 20 % (3/15) of our 
findings did not carry any drug resistance mutations. Based on drug class, the most common DRM were against 
NNRTI (81.25%) while DRM against NRTI were 62.5 %.Also, the most common mutations in this study were 
M184V, K65R in NRTI; K103N and Y188H in NNRTI. Our finding is common as long as these mutations are 
known to be common in cases of treatment failure and have been reported elsewhere (Johnson et al., 2013). They 
are associated with the use of 3TC, EFV and NVP, which have low genetic barriers towards resistance. The 
M184V wich his prevalent is known to cause resistance to 3TC and FTC, enhances the susceptibility to AZT, 
and delays the emergence of mutations associated with AZT and d4T (Johnson et al., 2013).His relatively high 
overall prevalence in this study may have consequences for second line treatment responses in HIV patients 
attending Kayanza district hospital .We also mention in our study the presence of K103N and Y188H which are 
more likely present in subtypes C (Delatorre & Bello, 2012) ..For NRTIs, the HIV drug resistance mutations 
found were against FTC, 3TC, and TDF while for the NNRTI the mutations found were against EFV and 
NVP) .This should be explained by the use of regimen based in 2NRTI+ 1NNRTI in the first line therapy. The 
utility of these agents as part of second- or third-line regimens is limited and then this should have an impact on 
second-line nucleoside analog therapy options with consequences of limit future treatment options. Also, we 
found HIV drug resistance mutations against D4T which have not even been introduced in Burundi Guide line. 
Further resistance testing on this drug regimen should be conducted before its introduction as a first line regimen 
in Burundi. In 15samples successfully sequenced, only 2 were patients under 18 years, from which did not 
harbour any mutation both in NRTIs and NNRTIs. The children should develop the transmitted or acquired drug 
resistance mutations. Although, due to the relatively small number of children enrolled in our study, these 
findings should not rule out presence of transmitted or acquired drug resistance mutations in HIV positive 
children at kayanza district hospital. A specific study with high number of children should be conducted to 
confirm our findings. Although our findings may not be generalized to all HIV clinics in Burundi but should 
indicate that some strategies to minimize HIVDR are needed .These should include improved availability and 
utilization of VL-based monitoring of ART response, and evaluation of the potential added value of HIV 
genotyping at treatment failure .In addition, high quality patient support for treatment adherence will contribute 
to protecting the efficacy of second line and subsequent therapy and improving overall treatment outcome . 
 
5. Conclusion 
In the conclusion, our study findings highlight the critical importance of Viral Load monitoring in Burundi 
programmes health-care and can help detecting Virological Failure earlier before extensive development of 
multidrug resistance which can render second- line unsuccessful and ineffective. Also, our study population had 
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high number of resistance mutations to all the NRTIs and NNRTIs used in HIV treatment in Burundi health care 
and the consequence is extremely high as long as none of the proposed drugs for third –line use are available. 
Effective monitoring of HIV positive patients using viral loads and drug resistance mutations surveillance is 
critical.Our study was a case control with a relatively small sample size of only 200 and thus may not be fully 
representative to the entire patients on ART in Burundi. Additional more robust studies as longitudinal cohort 
studies with high number of patients are needed to confirm our finding on virological outcomes and drug 
resistance mutations in HIV patients in Burundi.  
 
6. Conflict of interest declaration. 
The authors declare that they have no competing interests 
 
7. Genbank Accession Number: MK580981-MK580995. 
 
8. Acknowledgment 
This study was funded by the East Africa Public health Laboratory Network Project (EAPHLNP)/Burundi. The 
study also received technical support from the Kenya Medical Research institute. We are grateful also to all staff 
of Ngozi hospital, Kayanza hospital and Burundi National Reference Laboratory for their help in sample 
collection, processing and storage.  
 
9. REFERENCES  
Barth, R. E., van der Loeff, M. F. S., Schuurman, R., Hoepelman, A. I., & Wensing, A. M. (2010). 
Virological follow-up of adult patients in antiretroviral treatment programmes in sub-Saharan Africa: a 
systematic review. The Lancet Infectious Diseases, 10(3), 155–166. 
Bello, G., Passaes, C. P., Guimarães, M. L., Lorete, R. S., Matos Almeida, S. E., Medeiros, R. M., Morgado, 
M. G. (2008). Origin and evolutionary history of HIV-1 subtype C in Brazil: AIDS, 22(15), 1993–2000. 
Bulage, L., Ssewanyana, I., Nankabirwa, V., Nsubuga, F., Kihembo, C., Pande, G., Kiyaga, C. (2017). 
Factors associated with virological non-suppression among HIV-positive patients on antiretroviral therapy 
in Uganda, August 2014–July 2015. BMC Infectious Diseases, 17(1), 326. 
Cesar, C., Jenkins, C. A., Shepherd, B. E., Padgett, D., Mejía, F., Ribeiro, S. R., Cahn, P. (2015). Incidence 
of virological failure and major regimen change of initial combination antiretroviral therapy in the Latin 
America and the Caribbean: an observational cohort study. The Lancet HIV, 2(11), e492–e500.  
Delatorre, E. O., & Bello, G. (2012). Phylodynamics of HIV-1 Subtype C Epidemic in East Africa. PLoS ONE, 
7(7), e41904. 
Dessie, Y., Gerbaba, M., Bedru, A., & Davey, G. (2011). Risky sexual practices and related factors among 
ART attendees in Addis Ababa Public Hospitals, Ethiopia: A cross-sectional study. BMC Public Health, 
11(1). 
Endalamaw, A., Mekonnen, M., Geremew, D., Ambaw, F., Tesera, H., & Habtewold, T. D. (2018). 
Evidence that poor HAART adherence has a great impact on HIV/AIDS treatment failure more than 
severity of illness and opportunity of infection in Ethiopia: Systematic review and meta-analysis. BioRxiv. 
https://doi.org/10.1101/440743 
Etta, E. M., Mavhandu, L., Manhaeve, C., McGonigle, K., Jackson, P., Rekosh, D., T ebit, D. M. (2017). 
High level of HIV-1 drug resistance mutations in patients with unsuppressed viral loads in rural northern 
South Africa. AIDS Research and Therapy, 14(1). 
Foley, B., Leitner, T., Apetrei, C., Hahn, B., Mizrachi, I., Mullins, J. Yoon, H. (2015). HIV Sequence 
Compendium 2018, 450.  
 Grossman, Z., Istomin, V., Averbuch, D., Lorber, M., Risenberg, K., Levi, I., & Israel AIDS Multi-Center Study 
Group. (2004). Genetic variation at NNRTI resistanceassociated positions in patients infected with HIV-1 
subtype C. Aids, 18(6), 909- 915. 
Hamers, R. L., Sigaloff, K. C., Kityo, C., Mugyenyi, P., & de Wit, T. F. R. (2013). Emerging HIV-1 drug 
resistance after roll-out of antiretroviral therapy in sub-Saharan Africa. Current Opinion in HIV and AIDS, 
8(1), 19–26. 
Hawkins, C., Ulenga, N., Liu, E., Aboud, S., Mugusi, F., Chalamilla, G. Fawzi, W. (2016). HIV virological 
failure and drug resistance in a cohort of Tanzanian HIV-infected adults. Journal of Antimicrobial 
Chemotherapy, 71(7), 1966–1974. 
Johnson, V. A., Calvez, V., Günthard, H. F., Paredes, R., Pillay, D., Shafer, R. W. Richman, D. D. (2013). 
Update of the Drug Resistance Mutations in HIV-1: March 2013, 2. 
Kiptoo, M., Brooks, J., Lihana, R. W., Sandstrom, P., Ng’ang’a, Z., Kinyua, J., Songok, E. M. (2013). HIV-
1 drug resistance-associated mutations among HIV-1 infected drug-naïve antenatal clinic attendees in rural 
Kenya. BMC Infectious Diseases, 13(1). https://doi.org/10.1186/1471-2334-13-517 
Journal of Biology, Agriculture and Healthcare                                                                                                                                www.iiste.org 
ISSN 2224-3208 (Paper)  ISSN 2225-093X (Online) DOI: 10.7176/JBAH 
Vol.9, No.10, 2019 
 
61 
LeL Rency (2018). Molecular characterization of HIV and drug resistance mutations among HIV positive 
children attending Busia county referral hospital, Kenya, 81. 
 Lihana, R. W., Khamadi, S. A., Lubano, K., Lwembe, R., Kiptoo, M. K., Lagat, N., & Ichimura, H. (2009). HIV 
type 1 subtype diversity and drug resistance among HIV type 1-infected Kenyan patients initiating 
antiretroviral therapy. AIDS research and human retroviruses, 25(12), 1211-1217. 
Lihana Raphael W, Deogratius Ssemwenga, Alash'le Abimiku, and Nicaise Ndembi. (2012). HIV-1 
Diversity in Africa. A decade in review. AIDS, 14:83-100.  
Luvai, E. A. C. (2013.). Evaluation of predictors of HIV/AIDS treatment failure in patients with suspected 
virological and immunological failure from comprehensive care clinic in Nairobi, 2013, 89. 
Ndahimana, J. d’Amour, Riedel, D. J., Mwumvaneza, M., Sebuhoro, D., Uwimbabazi, J. C., Kubwimana, 
M., Nsanzimana, S. (2016). Drug resistance mutations after the first 12 months on antiretroviral therapy 
and determinants of virological failure in Rwanda. Tropical Medicine & International Health, 21(7), 928–
935. 
Nsanzimana, S., Remera, E., Kanters, S., Chan, K., Forrest, J. I., Ford, N. Mills, E. J. (2015). Life 
expectancy among HIV-positive patients in Rwanda: a retrospective observational cohort study. The Lancet 
Global Health, 3(3). 
Nyamache AK, Waihenya R., Muigai AW and Khamadi SA. (2011). Reverse Transcriptase Inhibitors Drug 
Resistance Mutations in Drug-Naive HIV Type 1 Positive Kenyan Individuals. East African medical 
journal, 88(1)4-8. 
Rusine, J., Asiimwe-Kateera, B., van de Wijgert, J., Boer, K. R., Mukantwali, E., Karita, E., Ondoa, P. 
(2013). Low Primary and Secondary HIV Drug-Resistance after 12 Months of Antiretroviral Therapy in 
Human Immune-Deficiency Virus Type 1 (HIV-1)-Infected Individuals from Kigali, Rwanda. PLoS ONE, 
8(8), e64345. https://doi.org/10.1371/journal.pone.0064345 
Summary, S. D. (2016). PEPFAR Burundi, 1–46. 
Tamura, K., Stecher, G., Peterson, D., Filipski, A., & Kumar, S. (2013). MEGA6: Molecular Evolutionary 
Genetics Analysis Version 6.0. Molecular Biology and Evolution, 30(12), 2725–2729.  
Vidal, N., Niyongabo, T., Nduwimana, J., Butel, C., Ndayiragije, A., Wakana, J., Peeters, M. (2007). HIV 
Type 1 Diversity and Antiretroviral Drug Resistance Mutations in Burundi. AIDS Research and Human 
Retroviruses, 23(1), 175–180. 
Ssemwanga, D., von Braun, A., Sekaggya-Wiltshire, C., Bachmann, N., Scherrer, A. U., Nanyonjo, M., 
Kambugu, A. (2018). HIV-1 Drug Resistance among Ugandan Adults Attending an Urban Out-Patient 
Clinic: JAIDS Journal of Acquired Immune Deficiency Syndromes, 78(5), 566–573. 
 
